It's no wonder the pharmaceutical companies want to get in on the medical cannabis gold rush, it seems to have efficacy for or all sorts of illnesses.
One of the latest is the following study by an Israeli team of scientists and cannabis's medicinal benefits for those suffering dementia.

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.
Shelef A1, Barak Y1, Berger U2, Paleacu D1, Tadger S1, Plopsky I1, Baruch Y1.
Author information

    1Abarbanel Mental Health Center, Bat-Yam, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
    2Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel.

Abstract
BACKGROUND:

Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD).
OBJECTIVE:

To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).
METHODS:

Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.
RESULTS:

Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p <  0.01) and NPI score were recorded (44.4 to 12.8; p <  0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, and sleep and caregiver distress.
CONCLUSION:

Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.
KEYWORDS:

Alzheimer’s disease; behavioral and psychological symptoms of dementia; cannabis; tetrahydrocannabinol

reference: http://www.ncbi.nlm.nih.gov/pubmed/26757043

 The problem is that the only way these pharmaceutical companies can really profit from cannabis is to synthesis it, and this can lead to severe consequences! as the following article demonstrates.

Drug company apologises after death of man left brain-dead in French trial

The private laboratory Biotrial was testing a new pain and mood disorder medication for Portuguese pharmaceutical company Bial on humans for the first time, in what is known as a Phase I trial, to test the drug's safety.

A total of 108 volunteers took part in the trial, 90 of whom received the drug at varying doses, while the rest were given placebos.

The six men who were hospitalised were the group which received the highest dose.

Bial chief executive Antonio Portela said he was "profoundly shocked by the situation" according to Portuguese news service LUSA.

"On my behalf and the behalf of Bial, I would like to express my deepest apologies to the family of the volunteer who died after participating in the Phase I trial of our experimental molecule," he said.

Mr Portela said Bial staff in France and Portugal were "working tirelessly to understand the causes of this accident".

Pierre-Gilles Edan, head of the neurology department at the Rennes hospital, said that three of the men were suffering a "handicap that could be irreversible" and another also had neurological problems.

The sixth volunteer had no symptoms but was being monitored.

"The 84 other volunteers exposed to the drug [have been contacted]," the hospital said.

Ten of them came in to be examined and did not have the "anomalies" seen in the hospitalised patients.

The incident is the worst of its kind ever to have taken place in France, which has launched three separate probes to determine whether the tragedy was caused by an error in the trial's procedures or in the substance tested.

Bial is cooperating with the investigation and vows it followed "international best practice" in developing the drug.

Biotral, the private laboratory administering the trial, said in a statement that it planned to work with the international scientific community to develop "changes to the standards governing such trials", without giving further details.

The company said the situation was "even more upsetting given that there is as yet no explanation".

Previous testing, notably on animals, had not thrown up any unusual results.
Other drug trial participants 'damaged for life'

Such serious mishaps are rare during the development of a drug, which begins in the laboratory before being animal tested and then three phases of human trials before it can be brought to market.

France's public body ONIAM, which is responsible for compensating the victims of medical accidents, said it had in its files only around 10 cases of accidents during drugs trials over the past 15 years, and "with consequences infinitely less serious" than the case in Rennes.

Although a rarity, there have been precedents in other countries.

A comparable accident took place in 2006 in London when six people taking German drug manufacturer TeGenero's TGN1412, which it was developing to treat certain types of cancer and other immunological diseases, fell seriously ill, with one suffering from multiple organ failure.

Two of the volunteers were in a critical condition and one lost all his fingers and toes.

The victims said they had the impression that their brains were on fire and that their eyes were coming out of their sockets.

Although they all survived, experts said at the time that their immune systems would be damaged for life.

reference: AFP


Considering the fact that no one has reportedly died from using cannabis, do we really need to synthesis this amazingly versatile plant, or would we prefer the pharmaceutical company stay away and let nature provide an organic version?